Bonesupport

BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the second quarter 2022.

STRONG SALES AND EARNING IMPROVEMENT

APRIL – JUNE 2022

• Net sales increased by 44 percent (32 percent at constant exchange rates¹) and amounted to SEK 74.6 million (51.8).
• The North America (NA) segment reported a sales increase of 58 percent (40 percent at constant exchange rate).
• The Europe & Rest of the World (EUROW) segment reported a sales increase of 26 percent (22 percent at constant exchange rates).
• The gross margin amounted to 89.0 percent (89.5).
• Operating result amounted to SEK -14.9 million (-25.9).
• Earnings per share, before and after dilution, were SEK -0.25 (-0.42).

JANUARY - JUNE 2022

• Net sales increased by 46 percent (33 percent at constant exchange rates) and amounted to SEK 141.0 million (96.6).
• The North America (NA) segment reported a sales increase of 61 percent (41 percent at constant exchange rate).
• The Europe & Rest of the World (EUROW) segment reported a sales increase of 27 percent (22 percent at constant exchange rates).
• The gross margin amounted to 89.7 percent (89.1).
• Operating result amounted to SEK -31.3 million (-45.6).
• Earnings per share, before and after dilution, were SEK -0.51 (-0.74).

"Market approval for CERAMENT G in the US - Most important milestone in the Company's history." Emil Billbäck, CEO

EVENTS DURING THE REPORTING PERIOD

• CMS, Centers for Medicare & Medicaid Services, communicated in end of April a favorable NTAP, New Technology Add-On Payments, ruling for CERAMENT G at USD 4,920.
• In May, the Company received market approval in the US from the US Food and Drug Administration (FDA), for the Company’s antibiotic-eluting product CERAMENT G, for the indication bone infection (osteomyelitis).
• In June, the Company announced that South Africa’s largest private health insurance company, Discovery Health, and the private hospital organizations Life Healthcare, Netcare, Melomed and Busamed will include BONESUPPORT’s antibiotic-eluting bone graft substitutes CERAMENT G and CERAMENT V in the reimbursement system.

EVENTS AFTER THE REPORTING PERIOD

• Nothing to report.